Clinical Trials

86 results for Prostate Cancer


Active Surveillance With or Without a 6 Months Apalutamide Treatment in Low Risk Prostate Cancer: A Phase II Randomized Multicenter Trial

  • Condition: Low Risk Prostate Cancer
  • Intervention: Drug: Apalutamide
  • Study ID: NCT03088124
View Trial

Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

  • Condition: Prostate
  • Intervention: Drug: Olaparib
  • Study ID: NCT03047135
View Trial

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

  • Condition: Post Prostatectomy
  • Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03160794
View Trial

Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer

  • Condition: Prostatic Neoplasms, Prostate Cancer
  • Intervention: Drug: PSMA PET/CT scan
  • Study ID: NCT02899312
View Trial

(18)F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

  • Condition: Prostate Neoplasms, Neoplasms, Prostatic, Prostate Cancer, Cancer Of Prostate
  • Intervention: Drug: 18F-DCFPyL
  • Study ID: NCT03181867
View Trial

A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: Nivolumab, Biological: Ipilimumab
  • Study ID: NCT02985957
View Trial

Robotic and Focused Stereotactic Radiation Treatment of Good Prognosis Prostatic Adenocarcinoma

  • Condition: Prostate Cancer
  • Intervention: Radiation: Cyberknife
  • Study ID: NCT03284151
View Trial

Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of t

  • Condition: Prostate Cancer
  • Intervention: Drug: Degarelix, Drug: approved GnRH agonist, Radiation: Radiotherapy
  • Study ID: NCT02799706
View Trial

Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer

  • Condition: Health Status Unknown, PSA Progression
  • Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
  • Study ID: NCT03234556
View Trial

Pilot Study of Focal Salvage HDR Prostate Brachytherapy

  • Condition: Prostate Cancer
  • Intervention: Radiation: focal salvage HDR prostate brachytherapy
  • Study ID: NCT01583920
View Trial

PSMA PET Imaging of Recurrent Prostate Cancer

  • Condition: Prostate Adenocarcinoma, Prostate Cancer
  • Intervention: Drug: Ga-HBED-iPSMA PET, Diagnostic Test: CT, Diagnostic Test: MRI
  • Study ID: NCT03204123
View Trial

A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)

  • Condition: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Niclosamide
  • Study ID: NCT03123978
View Trial

Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate

  • Condition: Locally Recurrent Prostate Cancer
  • Intervention: Radiation: Stereotactic Body Radiotherapy
  • Study ID: NCT03073278
View Trial

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Apalutamide, Drug: Degarelix, Drug: Abiraterone Acetate, Drug: Prednisone
  • Study ID: NCT03009981
View Trial

A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer

  • Condition: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
  • Intervention: Behavioral: behavioral dietary intervention, Behavioral: behavioral dietary intervention, Dietary Supplement: omega-3 fatty acid, Other: laboratory biomarker analysis
  • Study ID: NCT02176902
View Trial

A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer

  • Condition: Non-Resectable Pancreatic Cancer
  • Intervention: Biological: BPX-601, Drug: Rimiducid
  • Study ID: NCT02744287
View Trial

Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial

  • Condition: Prostate Cancer
  • Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
  • Study ID: NCT03482089
View Trial

A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies

  • Condition: Prostate Cancer
  • Intervention: Drug: Testosterone cypionate, Drug: Testosterone Enanthate, Drug: Abiraterone acetate, Drug: Enzalutamide
  • Study ID: NCT02090114
View Trial

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)

  • Condition: Prostate Cancer, Localized Malignant Neoplasm
  • Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT01766492
View Trial

A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer

  • Condition: Localized Prostate Cancer, Active Surveillance for Prostate Cancer
  • Intervention: Behavioral: Exercise
  • Study ID: NCT02435472
View Trial

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes

  • Condition: Prostate Cancer, Adenocarcinoma of the Prostate
  • Intervention: Drug: Olaparib Pill, Procedure: Prostatectomy
  • Study ID: NCT03432897
View Trial

Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer

  • Condition: Recurrent Prostate Cancer
  • Intervention: Drug: Verteporfin, Device: SpectraCure P18 System
  • Study ID: NCT03067051
View Trial

A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Carcinoma
  • Intervention: Drug: Gallium Ga 68-labeled PSMA-11, Procedure: Positron Emission Tomography
  • Study ID: NCT04216134
View Trial

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

  • Condition: Stage II Prostate Adenocarcinoma
  • Intervention: Radiation: Intensity-Modulated Radiation Therapy (IMRT), Radiation: Stereotactic Body Radiation Therapy (SBRT)
  • Study ID: NCT03367702
View Trial

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

  • Condition: Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Pro
  • Intervention: Drug: Carboplatin, Drug: Cisplatin, Drug: Docetaxel, Drug: Etoposide, Biological: Pembrolizumab
  • Study ID: NCT03582475
View Trial

Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
  • Study ID: NCT03753243
View Trial

A Phase 1/2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Ibrutinib
  • Study ID: NCT02643667
View Trial

Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
  • Study ID: NCT03568188
View Trial

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Combination Product: MVA-BN-Brachyury
  • Study ID: NCT04020094
View Trial

A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer

  • Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
  • Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
  • Study ID: NCT04253483
View Trial

PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy

  • Condition: Recurrent Prostate Cancer
  • Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
  • Study ID: NCT03718260
View Trial

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-guided Transurethral Ultrasound Ablation for Localized Prostate Cancer

  • Condition: Localized Prostate Cancer
  • Intervention: Device: MRI-TULSA
  • Study ID: NCT03814252
View Trial

Hypofractionated Radiosurgery for Localised Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Hypofractionated Radiosurgery
  • Study ID: NCT03795337
View Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
  • Study ID: NCT03767244
View Trial

Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
  • Study ID: NCT03531099
View Trial

68GA-PSMA FUSION PET/MRI FOR IMAGE-GUIDED PROSTATE BIOPSIES

  • Condition: Prostate Cancer
  • Intervention: Drug: 68Ga-PSMA
  • Study ID: NCT03689582
View Trial